WESTMINSTER, Colo.—Allos Therapeutics, Inc. and Mundipharma
International Corporation Limited have entered into a strategic collaboration
agreement focused on the co-development of FOLOTYN. Under the terms of the
agreement, Allos will retain full commercialization rights for FOLOTYN in the
United States and Canada, and Mundipharma will hold exclusive rights to
commercialize FOLOTYN in all other countries.

"Mundipharma is delighted to partner with Allos in the
development and commercialization of FOLOTYN and believes that it has worldwide
potential to become an important treatment alternative for patients," says Åke
Wikström, regional director Europe at Mundipharma International Limited.
"FOLOTYN represents a very meaningful addition to Mundipharma's oncology
pipeline and reinforces our commitment to improving patients' quality of life."

Mundipharma will pay Allos an upfront payment of $50 million
under the collaboration, as well as potential regulatory and commercial
progress- and sales-dependent milestone payments that could total up to $310.5
million. Allos is entitled to receive tiered double-digit royalties as well,
based on FOLOYTN's net sales within Mundipharma's licensed territories. Allos and
Mundipharma will fund development costs on a joint, 60:40 basis initially,
which will change to a 50:50 basis pending the achievement of certain
pre-defined milestones, such as approval of the Marketing Authorization
Application (MAA) in the European Union.

Mundipharma's development funding will support jointly
agreed-upon clinical development activities such as the Phase III studies of
FOLOTYN in previously undiagnosed peripheral T-cell lymphoma (PTCL) and in
combination with bexarotene in relapsed or refractory cutaneous T-cell lymphoma
(CTCL). Allos will supply FOLOTYN for Mundipharma's clinical and commercial
uses, pursuant to a separate supply agreement with Mundipharma Medical Company.

"Mundipharma is an ideal global partner," says Paul Berns,
president and chief executive officer of Allos Therapeutics, Inc. "They have
demonstrated hematology/oncology development, regulatory and commercial
capabilities with recent major regulatory and commercial successes in bringing
Levact (bendamustine) to market in Europe for non-Hodgkin lymphoma and other
blood cancers, as well as substantial resources to develop and commercialize
FOLOTYN."

FOTOLYN is a folate analogue metabolic inhibitor, and is the
first and only drug to be approved in the U.S. to treat patients with relapsed
or refractory PTCL. PTCL is a biologically diverse group of aggressive blood
cancers, and is also being studied in other hematologic malignancies. Allos
estimates that PTCL occurs in approximately 5,900 patients in the U.S. and
6,000 to 7,000 patients in the top five European markets annually.

"Lymphoma arising from T-lymphocytes remains a devastating
disease and new treatments are urgently needed," says Dr. Thomas Mehrling,
director of European Oncology at Mundipharma International Limited. "FOLOTYN,
if approved, may be in many countries the first drug to treat this cancer, and
this will allow us to work with hematologists to improve the treatment results
by developing new and hopefully even more effective drug combinations."

Allos is in the process of securing regulatory approval to
market FOLOTYN in the European Union for relapsed or refractory PTCL, and the
company's MAA was accepted for review last December.

"Our two
companies share a vision for bringing FOLOTYN to patients and believe this
collaboration will maximize the development, commercialization and market
potential of FOLOTYN in a variety of blood cancers," says Berns.